Intelligence · Clinical Pipeline

Boehringer Ingelheim Pipeline

All ClinicalTrials.gov programs at Boehringer Ingelheim — phase, modality, and trial IDs.

Programs: 31

Quick answer

Boehringer Ingelheim has 31 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

A Phase II, 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in patients with major depressive disorder

Boehringer Ingelheim

Major depressive disorder

phase 2 other active

1 trial
Afatinib once daily (OD)

Boehringer Ingelheim

Breast Neoplasms

phase 2 small molecule completed

1 trial
Avenciguat

Boehringer Ingelheim

Chronic Kidney Disease

phase 2 small molecule completed

1 trial
BI 1744 CL 2 Âµg

Boehringer Ingelheim

Pulmonary Disease, Chronic Obstructive

phase 2 small molecule completed

1 trial
BI 1810631

Boehringer Ingelheim

HER2-mutated or overexpressed/amplified solid tumours

phase 2 small molecule active

1 trial
BI 1815368, BI 1815368 Placebo, BI 1815368

Boehringer Ingelheim

Centre-involved diabetic macular edema

phase 2 small molecule active

1 trial
BI 1819479, Placebo, Film-coated tablet, matching in size, weight, colour and shape to BI 1819479 (both unit strengths), BI 1819479

Boehringer Ingelheim

idiopathic pulmonary fibrosis

phase 2 small molecule active

1 trial
BI 1839100, Placebo matching in size, weight, colour and shape to tablets of BI 1839100

Boehringer Ingelheim

Progressive pulmonary fibrosis (PPF), Idiopathic pulmonary fibrosis (IPF)

phase 2 small molecule active

1 trial
BI 3000202, BI 3000202, Placebo matching BI 3000202

Boehringer Ingelheim

Systemic lupus erythematosus

phase 2 small molecule active

1 trial
BI 3720931, BI 3720931

Boehringer Ingelheim

Cystic fibrosis

phase 2 small molecule active

1 trial
BI 3720931, Gadovist 1.0 mmol/ml solution for injection, Solvent for dilution for BI 3720931 inhaler solution, BI 3720931

Boehringer Ingelheim

Cystic fibrosis

phase 2 small molecule active

1 trial
BI 456906

Boehringer Ingelheim

Diabetes Mellitus, Type 2

phase 2 small molecule completed

1 trial
BI 655130

Boehringer Ingelheim

Dermatitis, Atopic

phase 2 small molecule completed

1 trial
BI 671800

Boehringer Ingelheim

Asthma

phase 2 small molecule completed

1 trial
BI 685509, Placebo matching BI 685509 PRD9566383, Placebo matching BI 685509 PRD9566375, BI 685509, BI 685509, Placebo matching BI 685509 PRD9566374

Boehringer Ingelheim

clinically significant portal hypertension (CSPH) in decompensated cirrhosis due to non-cholestatic liver disease

phase 2 small molecule active

1 trial
BI 690517, Jardiance 10 mg film-coated tablets, Placebo matching vicadrostat

Boehringer Ingelheim

chronic kidney disease

phase 2 small molecule active

1 trial
BI 764198

Boehringer Ingelheim

Proteinuric Kidney Diseases

phase 2 small molecule active

1 trial
BI 764198, Placebo to match BI 764198, BI 764198, BI 764198

Boehringer Ingelheim

Focal segmental glomerulosclerosis

phase 2 small molecule active

1 trial
BI 764524, Sham Injection Procedure

Boehringer Ingelheim

Diabetic retinopathy

phase 2 small molecule active

1 trial
BI 907828, BI 907828, BI 907828

Boehringer Ingelheim

Solid tumours

phase 2 small molecule active

1 trial
Herceptin 150 mg powder for concentrate for solution for infusion, Enhertu 100 mg powder for concentrate for solution for infusion, Fluorouracil Injection, 50 mg/ml, solution for injection, Ziihera 300 mg powder for concentrate for solution for infusion., Kadcyla 160 mg powder for concentrate for solution for infusion., Calciumfolinat Kabi 10 mg/ml Injektions-/Infusionslösung, Oxaliplatin Hikma 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Xeloda 500 mg film-coated tablets, Xeloda 150 mg film-co

Boehringer Ingelheim

gastroesophageal junction adenocarcinoma, metastatic gastric adenocarcinoma, metastatic breast cancer, metastatic colorectal cancer, esophageal adenocarcinoma

phase 2 small molecule active

1 trial
Matching placebo tablets without active substance, BI 706321, BI 706321, BI 706321, STELARA 130 mg concentrate for solution for infusion, STELARA 90 mg solution for injection in pre-filled pen

Boehringer Ingelheim

Crohn`s Disease (CD)

phase 2 small molecule active

1 trial
Pemetrexed EVER Pharma 25 mg/ml concentrate for solution for infusion, BI 1810631, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion.

Boehringer Ingelheim

locally advanced or metastatic NSCLC

phase 2 small molecule active

1 trial
Placebo matching BI 764198, BI 764198

Boehringer Ingelheim

Proteinuric kidney diseases

phase 2 small molecule active

1 trial
Placebo to BI 765423, BI 765423

Boehringer Ingelheim

Idiopathic Pulmonary Fibrosis (IPF)

phase 2 small molecule active

1 trial
Spesolimab

Boehringer Ingelheim

Generalized Pustular Psoriasis

phase 2 small molecule active

1 trial
Tipranavir

Boehringer Ingelheim

HIV Infections

phase 2 small molecule completed

1 trial
Vicadrostat

Boehringer Ingelheim

Chronic Kidney Disease

phase 2 small molecule active

1 trial
linagliptin low dose

Boehringer Ingelheim

Diabetes Mellitus, Type 2

phase 2 small molecule completed

1 trial
ribavirin (RBV)

Boehringer Ingelheim

Hepatitis C

phase 2 small molecule completed

1 trial
tiotropium-bromide

Boehringer Ingelheim

Asthma

phase 2 small molecule completed

1 trial

Frequently asked questions

How many pipeline programs does Boehringer Ingelheim have?

31 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Quick answer

A Phase II, 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in patients with major depressive disorder

Afatinib once daily (OD)

Avenciguat

BI 1744 CL 2 Âµg

BI 1810631

BI 1815368, BI 1815368 Placebo, BI 1815368

BI 1819479, Placebo, Film-coated tablet, matching in size, weight, colour and shape to BI 1819479 (both unit strengths), BI 1819479

BI 1839100, Placebo matching in size, weight, colour and shape to tablets of BI 1839100

BI 3000202, BI 3000202, Placebo matching BI 3000202

BI 3720931, BI 3720931

BI 3720931, Gadovist 1.0 mmol/ml solution for injection, Solvent for dilution for BI 3720931 inhaler solution, BI 3720931

BI 456906

BI 655130

BI 671800

BI 685509, Placebo matching BI 685509 PRD9566383, Placebo matching BI 685509 PRD9566375, BI 685509, BI 685509, Placebo matching BI 685509 PRD9566374

BI 690517, Jardiance 10 mg film-coated tablets, Placebo matching vicadrostat

BI 764198

BI 764198, Placebo to match BI 764198, BI 764198, BI 764198

BI 764524, Sham Injection Procedure

BI 907828, BI 907828, BI 907828

Matching placebo tablets without active substance, BI 706321, BI 706321, BI 706321, STELARA 130 mg concentrate for solution for infusion, STELARA 90 mg solution for injection in pre-filled pen

Pemetrexed EVER Pharma 25 mg/ml concentrate for solution for infusion, BI 1810631, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion.

Placebo matching BI 764198, BI 764198

Placebo to BI 765423, BI 765423

Spesolimab

Tipranavir

Vicadrostat

linagliptin low dose

ribavirin (RBV)

tiotropium-bromide

Frequently asked questions

Stay Ahead in Pharma